Silence Therapeutics Plc
Research Silence Therapeutics Plc (SLN) on Bullrun: market cap USD 465.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSLN
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 465.85M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 12.27M
- Free cash flowUSD 1.52M
Valuation Snapshot
latest market cap is USD 465.85M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 559.00K | -USD 88.61M | -USD 62.33M | 61.5% | -0.63 | USD 11.28M | USD 160.00K | USD 62.30M |
| FY2024 | USD 43.26M | -USD 45.31M | -USD 67.85M | 72.7% | -0.33 | USD 121.33M | USD 117.00K | USD 134.02M |
| FY2023 | USD 31.64M | -USD 54.23M | -USD 49.52M | 59.3% | -0.49 | USD 68.79M | USD 346.00K | USD 21.99M |
| FY2022 | USD 21.66M | -USD 50.33M | -USD 57.22M | 37.8% | -0.52 | USD 66.34M | USD 539.75K | USD 27.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 465.85M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 287.18M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 324.91M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 671.70M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 547.37M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 714.98M | n/a | n/a | n/a |
About Silence Therapeutics Plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Silence Therapeutics Plc's market cap?
Silence Therapeutics Plc's market capitalization is USD 465.85M.
What does Silence Therapeutics Plc do?
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.